"At NEICR we are on the forefront of this adventure, bringing state-of-the-art research programs from the pharmaceutical industry, academia, medical societies and patient advocacy groups to the New England and metro New York community."

During the past decade, New England Institute for Clinical Research conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 23 clinical trials were completed, i.e. on average, 62.2% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 19 clinical trials were completed. i.e. 118.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New England Institute for Clinical Research" #1 sponsor was "Eli Lilly and Company" with 14 trials, followed by "Allergan" with 6 trials sponsored, "Genentech, Inc." with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored and "Amgen" with 4 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New England Institute for Clinical Research" #1 collaborator was "Novartis" with 2 trials as a collaborator, "Solstice Neurosciences" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Banner Alzheimer's Institute" with 1 trials as a collaborator and "Clinvest Research, LLC" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "New England Institute for Clinical Research" are "Migraine" (9 trials), "Alzheimer's Disease" (6 trials), "Cerebral Palsy" (4 trials), "Chronic Cluster Headache" (3 trials) and "Muscle Spasticity" (3 trials). Many other conditions were trialed in "New England Institute for Clinical Research" in a lesser frequency.

Most popular intervention types in "New England Institute for Clinical Research" are "Drug" (36 trials), "Biological" (6 trials), "Other" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Galcanezumab" (4 trials), "Lasmiditan" (3 trials), "Ocrelizumab" (3 trials) and "[18F]GTP1" (3 trials). Other intervention names were less common.

The vast majority of trials in "New England Institute for Clinical Research" are 41 trials for "All" genders.

Currently, there are NaN active trials in "New England Institute for Clinical Research". undefined are not yet recruiting, 7 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in New England Institute for Clinical Research, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in New England Institute for Clinical Research, 5 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".